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Introduction
Cancer testis or germline (CG) antigen genes are expressed in 
germ cells and human tumors and encode immunogenic tumor 
antigens.1,2 Vaccines targeting CG antigens are undergoing clini-
cal testing in a variety of human malignancies that include mela-
noma, lung, and ovarian cancers.2 In addition to their significance 
as immunotherapy targets, CG gene products may contribute to 
oncogenesis. In particular, the MAGE gene family contains a 
MAGE homology domain (MHD), which in some instances can 
MAGEA11 is a cancer germline (cG) antigen and androgen receptor co-activator. Its expression in cancers other than 
prostate, and its mechanism of activation, has not been reported. In silico analyses reveal that MAGEA11 is frequently 
expressed in human cancers, is increased during tumor progression, and correlates with poor prognosis and survival. 
In prostate and epithelial ovarian cancers (EOc), MAGEA11 expression was associated with promoter and global DNA 
hypomethylation, and with activation of other cG genes. pharmacological or genetic inhibition of DNA methyltransferases 
(DNMTs) and/or histone deacetylases (hDAcs) activated MAGEA11 in a cell line specific manner. MAGEA11 promoter activity 
was directly repressed by DNA methylation, and partially depended on sp1, as pharmacological or genetic targeting of 
sp1 reduced MAGEA11 promoter activity and endogenous gene expression. Importantly, DNA methylation regulated 
nucleosome occupancy specifically at the -1 positioned nucleosome of MAGEA11. Methylation of a single Ets site near 
the transcriptional start site (Tss) correlated with -1 nucleosome occupancy and, by itself, strongly repressed MAGEA11 
promoter activity. Thus, DNA methylation regulates nucleosome occupancy at MAGEA11, and this appears to function 
cooperatively with sequence-specific transcription factors to regulate gene expression. MAGEA11 regulation is highly 
instructive for understanding mechanisms regulating cG antigen genes in human cancer.
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serve as a binding module for the RING family of ubiquitin E3 
ligases to promote degradation of the tumor suppressor protein 
p53.3 MAGEA11 facilitates co-activator recruitment to the andro-
gen receptor (AR) in the absence and presence of ligand, leading 
to activation of AR target genes in prostate cancer.4 Other CG 
genes make distinct contributions to oncogenesis.5-9 These stud-
ies suggest that CG antigen proteins have potential as therapeutic 
targets, beyond their current role in cancer immunotherapy.
We previously reported that the MAGEA11 promoter CpG 
island is hypermethylated in benign prostatic intraepithelial 
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prostate cancer is associated with activation of other CG anti-
gen genes, we measured MAGEA11 and three representative CG 
genes, MAGEA1, NY-ESO1 and XAGE1, in benign or malignant 
human prostate cells. Each of the CG genes was not significantly 
expressed in benign prostate cell lines, but was heterogeneously 
expressed in prostate cancer cell lines (Fig. 1D). MAGEA11 
was low to moderately expressed in benign prostate and most 
cancer cell lines, and elevated in LAPC-4 cells (Fig. 2A). 
LAPC-4 also displayed the highest expression of other CG genes 
(Fig. 1D). To further assess the correlation between MAGEA11 
and other CG gene expression, we analyzed primary prostate tis-
sue samples, which included benign prostatic hyperplasia (BP), 
androgen-stimulated prostate cancer (AS), and castration-recur-
rent prostate cancer (CR). MAGEA11 was highly expressed in a 
CR sample (CR1), that also was the only sample with significant 
expression of other CG genes (Fig. 1E). The data suggest that 
MAGEA11 is expressed concordantly with other CG genes in 
prostate cancer. Next, Oncomine was used to determine whether 
MAGEA11 is expressed in human cancers other than prostate. 
We found that MAGEA11 expression is elevated in a number 
of different human cancers, including esophageal and kidney 
(renal cell) tumors (Fig. S1A and C). MAGEA11 was expressed 
in 20–40% of these lesions, and its expression correlated with 
that of other MAGEA genes (data not shown). Furthermore, 
in both tumor types, MAGEA11 expression was associated 
with poor prognosis, similar to prostate cancer (Fig. S1B and 
D). We also analyzed MAGEA11 expression in human EOC, 
which has proven a useful disease model to study CG antigen 
gene regulation.18-20 Oncomine analysis of the Cancer Genome 
Atlas (TCGA) high-grade serous ovarian cancer data revealed 
significant elevation of MAGEA11 expression in EOC as com-
pared with normal ovary (Fig. 2A). MAGEA11 was expressed in 
~20% of EOC lesions in the TCGA (i.e., above the Oncomine 
median expression value and significantly elevated compared 
with normal ovary). Spurred by these data, we directly examined 
MAGEA11 expression in a set of primary EOC tissues. We used 
Affymetrix HG 1.0 ST microarrays to analyze the expression of 
MAGEA11 and other CG antigens in three NO and 40 EOC 
tissues described earlier.19 In agreement with the TCGA data, we 
observed significant elevation of MAGEA11 in EOC compared 
with NO (Fig. 2B). The TCGA data was explored further to 
determine whether MAGEA11 expression correlates with other 
CG genes. Genes with the highest correlation to MAGEA11 were 
known CG antigen genes, including other MAGEA family mem-
bers (Fig. 2C). In agreement with the TCGA, MAGEA11 expres-
sion correlated with other CG antigen genes in our EOC sample 
set (Fig. 2D).
MAGEA11 expression is associated with DNA hypomethyl-
ation at its TSS. In our previous analysis of prostate cancer cell 
lines, we observed DNA methylation proximal to the predicted 
MAGEA11 TSS, rather than at the 5' end of the promoter CpG 
island.10 Bisulfite clonal sequencing was performed in the normal 
PWR-1E prostate epithelial cell line, which has low MAGEA11 
expression, to determine whether proximal promoter meth-
ylation is critical for MAGE-A11 expression (Fig. 3A). PWR-1E 
cells displayed partial DNA methylation throughout most of the 
neoplasia, but can become hypomethylated in prostate cancer, 
particularly in castration-recurrent disease, and that this occurs 
in conjunction with gene activation.10 MAGEA11 appears to 
make a specific contribution to prostate cancer via its myriad of 
effects on AR signaling.4 However, two fundamental questions 
remain. First, is MAGEA11 activation a specifically selected 
event, or is it associated with activation of other CG genes, as a 
result of a global epigenetic alteration, e.g., global DNA hypo-
methylation?11 Second, is MAGEA11 activated in human cancers 
other than prostate and, if so, does this result from epigenetic 
alterations?
DNA methylation is intertwined with other epigenetic mech-
anisms that include histone acetylation, histone methylation, 
and nucleosome occupancy.12 Studies aimed to discern the rela-
tionship among these interdependent mechanisms at genes epi-
genetically activated in cancer, which include CG antigens, are 
limited. Recent work has explored the role of DNA methylation 
and histone modifications in CG antigen gene regulation,13-16 but 
information is lacking about the role of nucleosome occupancy in 
CG antigen gene regulation, or how this relates to other epigen-
etic marks. Also, epigenetic remodeling alone appears insufficient 
for CG gene activation, which additionally requires the action of 
sequence-specific transcription factors.1,17 How diverse epigenetic 
mechanisms and transcription factors are integrated to promote 
CG gene expression in cancer is unresolved.
An in silico analysis of MAGEA11 gene expression was con-
ducted in human cancer to begin to address these questions. 
Cell lines and primary tissues from prostate and epithelial ovar-
ian cancers (EOC) were analyzed to determine the relationship 
among MAGEA11 expression, promoter DNA hypomethylation, 
and global DNA hypomethylation. Genetic and pharmacologi-
cal approaches were applied to cancer cell lines to determine 
the relationship among DNA methylation, histone acetylation, 
and MAGEA11 gene expression. Promoter luciferase approaches 
addressed the impact of DNA methylation on MAGEA11 pro-
moter activity, and investigated the role of Sp1 in MAGEA11 gene 
regulation. The novel Methyltransferase Accessibility Protocol 
for individual templates (MAPit) sequencing method was used 
to assess the role of nucleosome occupancy in MAGEA11 gene 
regulation, and to determine how it is influenced by DNA 
methylation.
Results
MAGEA11 expression is elevated in multiple human cancers 
and is coordinately expressed with other CG antigen genes. We 
reported previously that MAGEA11 expression increases in cas-
tration-recurrent prostate cancer in a relatively small number of 
clinical specimens.10 To expand this analysis, we used Oncomine 
to analyze publically available microarray data sets for MAGEA11 
expression in prostate cancer and to determine the possible rela-
tionship to clinicopathology. This analysis confirmed MAGEA11 
expression in prostate cancer, and revealed significantly increased 
expression with increased Gleason grade (Fig. 1A), progression 
to metastasis (Fig. 1B), and in patients with early disease recur-
rence (Fig. 1C). To determine whether MAGEA11 expression in 
www.landesbioscience.com Epigenetics 851
addition to prostate cancer, we investigated DNA methylation 
relative to MAGEA11 gene regulation in EOC. Initially, bisul-
fite clonal sequencing was performed on NO and EOC samples. 
The MAGEA11 5' CpG island and TSS region were moderately to 
highly methylated in both NO and EOC samples that had low lev-
els of MAGEA11 expression, but were hypomethylated in an EOC 
sample (EOC38) expressing high levels of MAGEA11 (Fig. 3C). 
We developed a bisulfite pyrosequencing assay for MAGEA11 TSS 
methylation, to enable analysis of a larger number of biological 
samples and statistical testing of this association. Pyrosequencing 
established a significant indirect association between MAGEA11 
expression and TSS methylation in EOC (Fig. 3D).
5' CpG island, but the CpGs located adjacent to the predicted 
TSS were hypermethylated. Previously obtained methylation 
data for prostate cancer cell lines are shown for comparison10 
(Fig. 3A, TSS adjacent CpGs in red boxes), and MAGEA11 
expression and methylation in the four prostate cell lines analyzed 
are summarized in Figure 3B. MAGEA11 was expressed at the 
highest level in LAPC-4 cells, the only cell type in which the 
TSS region is hypomethylated. RLM-RACE was used to map the 
TSS of MAGEA11 in LAPC-4 cells, to confirm the relevance of 
our findings. The data confirmed that the TSS is located adjacent 
to the CpG sites showing differential methylation in the prostate 
cell lines (Fig. 3A, TSS indicated with right broken arrows). In 
Figure 1. MAGEA11 expression in human prostate cancer. (A–C) Oncomine analysis of MAGEA11 expression. Fold change, p-value, and microarray 
platform is indicated, and the title shows the first author of the referenced studies.61,62 Data are presented as a box and whiskers plot, with the box 
indicating the 25th to 75th percentiles, whiskers indicating the 10th and 90th percentiles, top and bottom points indicating the range, and center line 
indicating the median. (A) MAGEA11 expression as a function of prostate cancer Gleason grade. (B) MAGEA11 expression in primary and metastatic 
prostate cancer. (C) MAGEA11 expression as a function of prostate cancer recurrence at one year. (D) Expression of MAGEA11 and three representative 
cG antigen genes, MAGEA1, NY-ESO-1 and XAGE1 in prostate cell lines was measured using RT-qpcR. pWR-1E and RWpE-2 are cell lines derived from 
benign prostate epithelium, while the other cell lines were derived from prostate cancers. (E) Gene expression was measured as described in (D), using 
primary tissues derived from benign prostatic hyperplasia (Bp), androgen-stimulated prostate cancer (As), and castration-recurrent prostate cancer 
(cR). Absence of a bar indicates that no expression was detected.
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association between MAGEA11 expression and LINE1 methyla-
tion suggested that MAGEA11 methylation and LINE1 methyla-
tion are associated. Consistent with this hypothesis, there was a 
significant association between MAGEA11 TSS methylation and 
LINE1 methylation in prostate cancer and EOC (Fig. 4E and F).
To further investigate the relationship between promoter 
and global DNA methylation and MAGEA11 expression, we 
used a human colorectal cancer somatic cell genetic knockout 
system in which the cytosine DNA methyltransferase enzymes 
DNMT1 and DNMT3b have been targeted alone or in com-
bination.21 MAGEA11 expression was undetectable in wild-
type HCT116 cells, increased in single DNMT1 or DNMT3b 
knockout HCT116 cells, and was highest double knockout 
DNMT1/3b HCT116 cells (DKO) (Fig. S2A; note that expres-
sion was plotted on a log scale). In agreement with the expres-
sion results, the MAGEA11 promoter was hypermethylated in 
wild-type HCT116 cells with progressively greater hypomethyl-
ation in DNMT3b−/−, DNMT1−/−, and DKO cells, respectively 
(Fig. S2B). These results support the idea that TSS hypometh-
ylation is required for high MAGEA11 expression, since only 
HCT116 DKO cells showed robust hypomethylation at the 
MAGEA11 expression and hypomethylation is associated 
with global DNA hypomethylation. We used LINE1 methyla-
tion as a biomarker for global DNA methylation status to examine 
whether global DNA hypomethylation is related to MAGEA11 
activation in cancer.19,20 LINE1 pyrosequencing is a cost effec-
tive assay and readout for overall global methylation in cancer, 
as there is a direct correlation between LINE1 and 5mdC in can-
cer tissues.20 In prostate cell lines, an inverse correlation between 
MAGEA11 expression and LINE1 methylation was observed, 
but did not reach statistical significance (Fig. 4A; Spearman r = 
−0.455, p = 0.27). In clinical prostate tissues, LINE1 was hypo-
methylated to the greatest extent in the CR tumor that expressed 
MAGEA11 (Fig. 4B). We analyzed two groups of EOC lesions 
characterized by distinct LINE1 methylation (i.e., hypometh-
ylated and hypermethylated), and NO samples as controls, to 
more rigorously test this association (Fig. 4C). While MAGEA11 
expression was higher in both EOC sample groups compared 
with NO, its expression was highly elevated in hypomethylated 
vs. hypermethylated EOC (Fig. 4C). Moreover, there was a sig-
nificant inverse correlation between MAGEA11 expression and 
LINE1 methylation in all EOC samples (Fig. 4D). The indirect 
Figure 2. MAGEA11 expression in epithelial ovarian cancer (EOc). (A) Oncomine analysis of MAGEA11 mRNA expression in TcGA data.63 Fold change,  
P value, and microarray platform is indicated. Data presentation is as described in Figure 1. (B) Oncomine analysis of the genes most closely correlated 
with MAGEA11 in TcGA data. (C) MAGEA11 mRNA expression was determined in three normal ovary samples and 40 EOc samples using Affymetrix hG 
1.0sT microarrays. Two-tailed t-test results are shown. (D) Expression of MAGEA11 and other cG antigen genes was determined by Affymetrix microar-
ray, as described in (C). spearman test r values and P values for correlation with MAGEA11 are shown.
www.landesbioscience.com Epigenetics 853
hypermethylated, MAGEA11 was induced by decitabine but not 
by TSA, with the highest level of induction following combina-
tion treatment (Fig. 5A and B). These findings suggest that DNA 
methylation plays a primary role in MAGEA11 gene repression, 
and histone deacetylation plays an accessory role, in cells with 
TSS-hypermethylated MAGEA11. In LAPC-4 cells, in which 
the MAGEA11 TSS is hypomethylated, TSA caused substantial 
induction of MAGEA11 while decitabine did not, although the 
combination treatment still showed the greatest effect (Fig. 5C). 
These findings suggest that HDACs can still repress MAGEA11, 
when TSS DNA methylation levels are lower. In agreement, 
ChIP analysis showed that TSA treatment increased histone 
acetylation at lysine 9 (H3K9-Ac) at the MAGEA11 promoter in 
LAPC-4 cells (Fig. S3A). In contrast to DU145 and PC-3 cells, 
TSA treatment did not influence MAGEA11 expression in benign 
PWR-1E prostate cells (Fig. 5D). This is suggestive of cancer-
specific alterations in HDACs, as has been reported.26
MAGEA11 TSS. The effect of DNMT loss on MAGEA11 pro-
moter methylation paralleled the effect on global DNA methyla-
tion in these cell lines,14,21,22 which provides additional evidence 
for a link between global DNA hypomethylation and MAGEA11 
expression.
DNMT and histone deacetylase (HDAC) inhibitors induce 
MAGEA11 expression in a cell type specific manner. In addition 
to DNA methylation, histone modification can play an important 
role in CG gene regulation.14-16,23 A pharmacological approach 
was used in prostate cell lines to investigate the relative roles 
of DNA methylation and histone deacetylation on MAGEA11 
repression. Prostate cell lines were treated with the pan-DNMT 
inhibitor decitabine (DAC) and the pan-class I/II HDAC inhibi-
tor Trichostatin A (TSA),24,25 individually or in combination. 
Decitabine treatment was confirmed to reduce MAGEA11 pro-
moter DNA methylation levels (data not shown). In DU145 and 
PC-3 prostate cancer cells in which the MAGEA11 TSS region is 
Figure 3. MAGEA11 promoter methylation and expression in prostate cancer and EOc. (A) sodium bisulfite clonal sequencing of the MAGEA11 
promoter region was performed on the indicated cell lines. The transcriptional start site (Tss), as determined by RLM-RAcE, is indicated by the right 
broken arrow, and the coordinates of the analyzed region are shown in the upper left panel. Filled and open circles indicate methylated and unmeth-
ylated cpG sites, respectively, and each row represents one sequenced allele. The red box indicates three Tss-adjacent cpG sites. (B) summary of 
MAGEA11 bisulfite sequencing and mRNA expression data in prostate cell lines. Methylation percentages for the entire MAGEA11 5' cpG island (cGI) or 
for the three Tss-resident cpGs were calculated from (A), and MAGEA11 expression was determined by RT-qpcR. (C) MAGEA11 promoter methylation 
and mRNA expression in one normal ovary (NO) and four EOc samples were determined using bisulfite clonal sequencing (>10 alleles), and Affymetrix 
microarray, respectively. (D) MAGEA11 mRNA expression indirectly correlates with MAGEA11 Tss methylation in EOc. MAGEA11 expression and methyla-
tion of three Tss-resident cpG sites in 16 EOc samples was determined by RT-qpcR and bisulfite pyrosequencing, respectively. Five samples that did 
not express measurable MAGEA11 are plotted on the x-axis. spearman test results are shown.
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(Fig. 6A). Each construct was active in prostate cell lines, in 
the order, C3 > C2 > C1 > C4, in all 3 cell lines (Fig. 6B). 
Notably, C3, which contains a cluster of 10 CpG sites embedded 
within 10 consensus Sp1 binding sites, had the highest activity, 
while C4, which was identical to C3 but did not contain the 
Sp1 region, had the lowest activity (Fig. 6A–C). This suggested 
MAGEA11 is directly repressed by DNA methylation, and 
activated by Sp1. A luciferase reporter gene assay was used 
to determine the impact of DNA methylation on MAGEA11 
promoter activity in prostate cancer cells. Four constructs, C1 
through C4, were prepared that terminate 55 bp downstream 
of the MAGEA11 TSS and span different lengths upstream 
Figure 4. MAGEA11 expression and methylation and global DNA methylation. (A) MAGEA11 expression and LINE1 methylation in human prostate cell 
lines. MAGEA11 expression was determined by RT-qpcR and LINE1 methylation was determined by pyrosequencing. pWR-1E and RWpE-2 are derived 
from normal prostate epithelium, while other cell lines are derived from prostate cancer. spearman test showed an inverse association between MA-
GEA11 expression and LINE1 methylation, which did not reach statistical significance (R = −0.455, p = 0.267). (B) MAGEA11 expression and LINE1 methyl-
ation in primary prostate tissues. Measurements were determined as described in (A). (C) MAGEA11 expression and LINE1 methylation in normal ovary 
and EOc with divergent LINE1 methylation. MAGEA11 expression and LINE1 methylation were determined as described in (A). MAGEA11 expression is 
plotted on a log axis and note that five samples in the hypermethylated EOc group did not express measurable MAGEA11. The mean LINE1 methylation 
level in three sample groups is shown below the x-axis. Two-tailed t-test results are shown. (D) MAGEA11 expression and LINE1 methylation are indi-
rectly associated in EOc. MAGEA11 expression was plotted vs. LINE1 methylation in EOc samples from both EOc groups shown in (C). spearman test 
results are shown. (E) MAGEA11 Tss methylation and LINE1 methylation are directly associated in prostate cancer. Methylation was determined using 
bisulfite sequencing (MAGEA11) and pyrosequencing (LINE-1). spearman test results are shown. (F) MAGEA11 Tss methylation and LINE1 methylation 
are directly associated in EOc. Methylation was determined using pyrosequencing. spearman test results are shown.
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constructs, with the C3 construct showing highest activity. 
Unexpectedly, HpaII, which methylates only 1–2 CpGs in the 
C1-C4 constructs, strongly repressed MAGEA11 promoter activ-
ity, similar to M.SssI, which methylates all CpG sites in these 
constructs (Fig. 6E). Similar results were obtained in other pros-
tate cell lines (data not shown). The two HpaII sites within the 
MAGEA11 promoter region are found within consensus Ets tran-
scription factor binding sites (Fig. 6C). Thus, the data suggest 
that methylation at one or both of these sites impairs MAGEA11 
promoter activity. Consistent with this notion, previous studies 
have implicated Ets sites in methylation-dependent promoter 
activity of other MAGEA gene family members.1,17,27,28
Elevated activity of the C3 construct relative to C4 sug-
gested that Sp1 site binding factors regulate MAGEA11. Sp1, 
the prototype member of the Sp1 family, is expressed widely 
in benign and malignant tissues, and contributes to oncogen-
esis.29 Western blot analysis demonstrated that prostate cell 
lines express nuclear Sp1 protein (Fig. 7A). The Sp1 inhibitor 
that Sp1 factors may contribute to MAGEA11 gene activity. In 
addition, the data suggested the presence of repressive motifs in 
the 5' region of MAGEA11, based on the lower activity levels 
of C1 and C2, relative to the C3 construct. It was also notable 
that DU145 cells showed highest levels of MAGEA11 promoter 
activity, while the endogenous MAGEA11 gene is silenced by 
DNA methylation in this cell type (Fig. 6B; Fig. 3B). Thus, 
DU145 cells may express factors necessary to drive MAGEA11 
expression, but these factors may be restricted at the endogenous 
gene locus by DNA methylation.
We methylated the C1 through C4 inserts, but not the vector 
sequences, using HpaII or M.SssI, which methylate 5'-CCGG-3' 
or 5'-CG-3' sites, respectively, to directly determine the impact of 
DNA methylation on MAGEA11 promoter activity. Digestion of 
the plasmid inserts with HpaII and McrBc restriction enzymes 
confirmed their expected methylation status (Fig. 6D). The 
results in PC-3 cells are shown in Figure 6E. Mock methylated 
constructs showed a similar pattern of activity as unmethylated 
Figure 5. Epigenetic modulatory drugs induce MAGEA11 expression. MAGEA11 expression was measured by RT-qpcR following treatment of benign 
prostate or prostate cancer cell lines with vehicle (pBs/DMsO), Trichostatin A (TsA), and/or decitabine (DAc), as described in “Materials and Methods.” 
(A) DU145 cells, (B) pc-3 cells, (C) LApc-4 cells, (D) pWR-1E cells. We noted that the MAGEA11/GAPDH copy number in control LApc-4 cells appeared 
substantially lower than observed in other experiments, likely due to repression by DMsO. This effect was also observed in Figure 7C.
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nucleosome occupancy are based on population averaging, which 
does not give single molecule information, nor allow integration 
of endogenous DNA methylation status.32,33 A newly developed 
method, MAPit (a.k.a., NOME-seq), overcomes these limita-
tions.34,35 In MAPit, isolated nuclei are treated with CviP1, an 
enzyme that methylates nucleosome-free 5'-GC-3' sites.32 After 
CviP1 modification, gDNA is recovered and subjected to bisul-
fite clonal sequencing to simultaneously reveal nucleosome 
occupancy, as defined by protection from GC methylation, and 
endogenous DNA methylation, i.e., CG methylation.36 MAPit 
allowed us, for the first time, to examine the relationship between 
DNA methylation and nucleosome occupancy in CG gene regu-
lation, using MAGEA11 as a model.
To determine whether DNA methylation status influences 
MAGEA11 nucleosome occupancy, we utilized the isogenic 
Mithramycin A (MitA)30 was used to address whether Sp1 factors 
are involved in MAGEA11 regulation. MitA treatment caused a 
dose-dependent reduction in MAGEA11 promoter activity and 
endogenous MAGEA11 expression in LAPC-4 cells (Fig. 7B 
and C). In addition, decitabine-mediated MAGEA11 induc-
tion in PC-3 cells was inhibited in a dose-dependent manner by 
MitA treatment (Fig. 7D). Furthermore, Sp1 targeting siRNAs 
reduced MAGEA11 expression in LAPC-4 cells, proportional to 
the degree of knockdown (Fig. 7E and F). Together, the results 
demonstrate that Sp1, and potentially related factors, activate 
MAGEA11.
DNA methylation status influences nucleosome occupancy 
at the MAGEA11 promoter. DNA methylation and histone 
modifications can impact gene expression via effects on pro-
moter nucleosome occupancy.31 Traditional methods to map 
Figure 6. MAGEA11 promoter activity and repression by DNA methylation. (A) Diagram of the MAGEA11 5' region and MAGEA11 promoter luciferase 
constructs. The MAGEA11 promoter region, Tss, first part of exon I (gray box), and the cpG island (cGI) are indicated. Four promoter constructs were 
generated by pcR (c1-c4). The key indicates the location of cpG sites, Ets sites (which correspond to hpaII sites), the sp1 site cluster, and the three 
Tss-resident cpG sites examined by bisulfite pyrosequencing. (B) c1-c4 constructs were transfected into the indicated prostate cancer cell lines, and 
promoter activity was measured. cells treated with the transfection reagent alone served as a negative control. (C) sequence of the two Ets sites and 
the sp1 site cluster in the MAGEA11 promoter. cpG dinucleotides are indicated with red font. The two consensus Ets sites each contain an hpaII recog-
nition sequence (5'-ccGG-3'). The sp1 cluster contains 10 embedded cpG sites. (D) confirmation of the methylation status of MAGEA11 promoter con-
struct inserts. Inserts were mock-methylated (M), methylated with hpaII (h), or with M.sssI (s). Methylation status was verified by digestion with hpaII 
restriction endonuclease (top panel) or McrBc endonuclease (bottom panel). The sequence specificity of each nuclease is shown at left. (E) MAGEA11 
promoter repression by methylation. Inserts verified as shown in (C) were ligated into the pGL3-basic vector, transfected into pc-3 cells, and promoter 
activity was measured. The number of hpaII and M.sssI sites in each construct is indicated below the graph.
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noted that the region of the MAGEA11 promoter with signifi-
cant variation in GC methylation between HCT116 and DKO 
cells was localized to the area upstream of the TSS, and spanning 
approximately 200 bp. This distance is greater than the length 
of one nucleosome (147 bp), and includes what has been referred 
to as the -1 nucleosome.38 In contrast, the areas upstream and 
downstream showed low GC methylation in both HCT116 and 
DKO cells, which suggests continued nucleosome occupancy at 
these locations. Occupancy at the -1 nucleosome position may 
be critical for MAGEA11 expression, potentially by impact-
ing RNA Polymerase II (RNAP II) binding.38 In agreement, 
ChIP revealed increased RNAP II binding to the MAGEA11 
HCT116/DKO cell model system described earlier.21 MAPit 
was conducted on HCT116 wild type and DNMT1/3b 
knockout (DKO) cells, and the results were analyzed using 
MethylViewer.37 In agreement with our standard bisulfite clonal 
sequencing results, MAGEA11 was hypermethylated at CG 
sites in HCT116 cells relative to DKO cells (Fig. 8A and B). 
In contrast, GC methylation increased in DKO cells relative to 
HCT116 wild-type cells, consistent with nucleosome depletion 
at the MAGEA11 promoter (Fig. 8A and B). Approximately half 
of the sequenced alleles in DKO cells showed increased CviP1 
methylase accessibility. Decitabine-treated HCT116 cells dis-
played MAPit results similar to DKO cells (data not shown). We 
Figure 7. sp1 contributes to MAGEA11 promoter activity and gene expression. (A) sp1 protein expression was determined by western blot analysis of 
the indicated cell lines. c and N refer to cytosolic and nuclear extracts, respectively. (B) Mithramycin A (MitA) treatment reduces MAGEA11 promoter 
activity. LApc-4 cells were simultaneously transfected with the c3 construct and treated with DMsO (vehicle) or the indicated concentrations of MitA. 
cell extracts were harvested 24 h post-treatment and used for luciferase assay. (C) MitA treatment represses MAGEA11 mRNA expression. LApc-4 
cells were treated with DMsO or MitA for 24 h, and RNA extracts were used to measure MAGEA11 expression by RT-qpcR. (D) MitA treatment sup-
presses decitabine-mediated MAGEA11 induction. pc-3 cells were treated with decitabine (DAc) and/or MitA alone or in combination. RNA extracts 
were harvested five days after initiation of treatment, and were used to measure MAGEA11 expression by RT-qpcR. (E) sp1 knockdown in LApc-4 cells. 
LApc-4 cells were transfected with two different sp1 targeting siRNAs, or with a control non-targeting siRNA, once daily for 48 h. 48 h post-treatment, 
whole cell extracts were prepared and used for western blot analysis. (F) sp1 knockdown reduces MAGEA11 expression. LApc-4 cells were treated as 
described in (E), and RNA extracts were prepared 48 h post treatment and used for RT-qpcR analysis of MAGEA11.
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Figure 8. MApit analysis of MAGEA11 promoter nucleosome occupancy. MApit data were analyzed using MethylViewer.37 Each row indicates one indi-
vidual sequenced allele, and the approximate nucleotide coordinates in relation to the Tss are indicated below each data panel. The key to symbols 
used is shown at top. The areas highlighted orange indicate cvip1-accessible regions (e.g., nucleosome-free regions) and were defined according to 
the “3 + 2 rule,” i.e., regions of three consecutive G-m5c sites broken by two consecutive Gc sites. The vertical magenta lines delineate the termini of 
the region analyzed by traditional bisulfite clonal sequencing in Figure S2 (for hcT116 and DKO) and Figure 3 (for pc-3). (A) hcT116 cells. (B) DKO cells. 
(C) pc-3 cells.
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DNA hypomethylation at TSS-resident CpG sites. In addi-
tion, MAGEA11 expression and hypomethylation are associated 
with global DNA hypomethylation, as evidenced both by pri-
mary human tumor data from prostate and ovarian cancers, and 
by data from a genetic DNMT knockout cell system. DNMT 
and HDAC inhibitors can both activate MAGEA11 expres-
sion, in some cases in a synergistic fashion. Also, we showed 
that MAGEA11 promoter activity was repressed directly by 
DNA methylation and that Sp1, or related factors, contributes 
to MAGEA11 promoter activity and endogenous gene expres-
sion. For the first time, we have reported the role of nucleosome 
occupancy in CG antigen gene regulation, using MAGEA11 as a 
model. Our MAPit data provide evidence that: (1) DNA methyl-
ation specifically regulates nucleosome occupancy at the -1 posi-
tioned nucleosome at the MAGEA11 promoter, (2) methylation 
of an Ets consensus binding site positioned near the TSS closely 
correlates with MAGEA11 -1 nucleosome occupancy, (3) partial 
methylation at the 5' end of the Sp1 site cluster in the MAGEA11 
promoter CpG island correlates with -1 nucleosome depletion, 
and (4) a region overlapping the 3' end of the Sp1 site cluster is 
protected from CviP1 methylation, potentially by binding of the 
TIC, or by a transcription factor.
Based on the current study, we outline a schematic of 
events leading to MAGEA11 gene expression in human cancer 
(Fig. 9A). The initiating event driving MAGEA11 gene expres-
sion in cancer is likely to be global DNA hypomethylation. 
While the underlying cause of global DNA hypomethylation in 
cancer is yet to be demonstrated,11 it could reflect alterations of 
higher-order chromatin structure in the cancer cell nucleus.44,45 
MAGEA11 TSS hypomethylation is a target of global DNA 
hypomethylation, and this event provides a chromatin tem-
plate permissive for gene activation by members of the Ets and 
Sp1 transcription factor families. Our results also indicate that 
HDACs contribute to MAGEA11 gene repression, either as an 
accessory to DNA methylation or as a primary repressive mecha-
nism in some cancer cells. Full removal of epigenetic repression 
in certain tumors may allow high level MAGEA11 expression 
and downstream oncogenic effects (e.g., AR activation in pros-
tate cancer). Conversely, high expression of MAGEA11 may 
render tumor cells susceptible to immunotherapeutic approaches 
targeting this antigen.46 A model for the MAGEA11 gene config-
uration in the fully repressed and fully activated state is shown in 
Figure 9B. As indicated, a central aspect of the model is -1 nucleo-
some occupancy, which is based on the MAPit data. Preliminary 
analysis of additional cell types, including LAPC-4, also sup-
port the importance of -1 nucleosome occupancy in MAGEA11 
regulation (data not shown). The observation that DNA hypo-
methylation leads to nucleosome depletion at the MAGEA11 TSS 
has increased importance when put in the context of a recent 
report. Pandiyan et al. showed that only a small subset (<2%) 
of genes undergoing hypomethylation in DKO cells, or follow-
ing decitabine treatment, show changes in promoter nucleosome 
occupancy.47 The authors proposed that these target genes may be 
the most important for regulating tumorigenesis in the context of 
DNA hypomethylation. Experimental validation of MAGEA11 
as one of these targets further suggests an oncogenic role for this 
-1 nucleosome region in DKO cells, relative to HCT116 cells 
(Fig. S3B). In HCT and DKO cells, we additionally noted that 
the endogenous methylation status of specific CpG sites accu-
rately predicted -1 nucleosome occupancy. Notably, these sites 
included the 3' HpaII/Ets site mentioned earlier, in the context 
of luciferase assays (Fig. 8A and B).
As shown earlier, the prostate cancer cell line PC-3 displayed 
low to moderate levels of MAGEA11 expression along with 
heterogeneous methylation of the MAGEA11 5' CpG island 
(Fig. 3A and B). MAPit analysis of this cell line allowed us 
to further examine the relationship between MAGEA11 DNA 
methylation, gene expression, and nucleosome occupancy. PC-3 
cells showed a heterogeneous pattern of nucleosome occupancy, 
with nucleosome depletion at the -1 nucleosome region in some 
alleles (Fig. 8C). In addition, 3' Ets site methylation was closely 
associated with nucleosome occupancy in PC-3 cells, as was 
methylation of two other 5' CpG sites (Fig. 8C). Unexpectedly, 
nucleosome depletion in PC-3 cells correlated with partial 
methylation at the 5' end of the Sp1 cluster region, while com-
plete hypomethylation of this region correlated with nucleo-
some occupancy (Fig. 8C). This trend was also readily apparent 
in DKO cells (Fig. 8B). Finally, we noted that the region of 
CviP1 accessibility in the -1 nucleosome region was interrupted 
by a short stretch of DNA that overlapped the 3' end of the 
Sp1 cluster region (Fig. 8C). This pattern was also observed in 
some of the sequenced alleles of DKO cells (Fig. 8B). The small 
CviP1-protected region within the larger nucleosome-free -1 
region may correspond to a region bound by the transcriptional 
initiation complex (TIC) and/or a transcription factor. Taken 
together, our results indicate strong interdependence among 
DNA methylation, -1 nucleosome occupancy, and MAGEA11 
gene expression.
Discussion
MAGEA11 is a nuclear protein identified in a yeast two-hybrid 
screen for proteins that bind the human androgen receptor 
(AR).39,40 In addition to AR, MAGEA11 is now known to acti-
vate human progesterone receptor-B, and its capacity as a steroid 
receptor activator is in part mediated through interactions with 
the p300 histone acetyltransferase.41,42 In addition, MAGEA11 
can activate AR signaling by forming a molecular bridge between 
transcriptionally active AR dimers, and also contributes to pros-
tate cancer cell growth.4 Most recently, MAGEA11 has been 
found to promote oncogenesis by targeting the retinoblastoma 
(RB) pathway.43 This latter activity may provide the selective 
pressure for MAGEA11 expression in a variety of human can-
cers, as reported here. Because of its apparent role in tumori-
genesis, MAGEA11 is an important potential target of cancer 
vaccines and therapeutics. MAGEA11 expression could also serve 
as a biomarker of cancer prognosis, based on our data showing 
that MAGEA11 is expressed in a variety of human cancers, in a 
manner that correlates both with tumor progression and reduced 
survival.
MAGEA11 activation in cancer occurs in conjunction with 
the activation of other CG genes, and in association with 
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protein. More generally, and also in agree-
ment with the data reported here, a recent 
report indicated that DNA methylation dic-
tates nucleosome occupancy at numerous 
genomic loci in human cancer cells.48
In addition to revealing a general asso-
ciation between DNA methylation den-
sity and nucleosome occupancy at the 
MAGEA11 promoter, MAPit also revealed 
strong correlation between methylation of a 
specific Ets site and nucleosome occupancy 
at MAGEA11. This finding is particularly 
striking when considered in the context of 
our promoter activity data, which demon-
strated that methylation at this site alone 
fully repressed the transcriptional activity of 
the MAGEA11 C3 and C4 promoter con-
structs. In agreement with our observations 
on MAGEA11, other recent work has impli-
cated Ets site hypomethylation in driving 
the activation of specific genes in cancer.49 
Additional studies are required to define 
which Ets family member(s) are respon-
sible for MAGEA11 regulation at this site. 
While the large size and overlapping target 
sequences of this protein family will make 
this task challenging,50 the question may 
be amenable to a focused RNAi screening 
approach.
An additional key finding from MAPit 
relates to the relationship between methyla-
tion of the Sp1 site cluster and nucleosome 
occupancy. Surprisingly, the MAGEA11 
promoter showed nucleosome depletion 
only when the Sp1 site cluster was partially 
(but not fully) methylated. How Sp1 bind-
ing is impacted by DNA methylation is con-
troversial, and it appears likely to be based 
on the specific promoter and cell type.51-55 
Although our preliminary data indicate 
that Sp1 can directly bind at the MAGEA11 
promoter in prostate cancer cells (data not 
shown), additional detailed studies are 
required to determine the epigenetic con-
text in which this binding occurs. Finally, 
MAPit showed a small CviP1 footprint over-
lapping the 3' end of the MAGEA11 Sp1 site 
cluster, in cells in which the flanking regions 
were CviP1 accessible (i.e., nucleosome-
depleted). This footprint is likely to indicate 
binding of the TIC, which can occur at Sp1 
sites in CpG island promoters that lack a 
consensus TATA box,56 as is the case for the 
MAGEA11 promoter. Highly similar foot-
prints, potentially related to binding of the 
TIC, have been observed by others.57-59 This 
Figure 9. MAGEA11 gene regulation in human cancer. (A) Flowchart of events involved in the 
activation of MAGEA11 expression in cancer. (B) schematic of MAGEA11 promoter configuration 
in the fully repressed (top) and fully activated states (bottom). Open and filled lollipops indicate 
unmethylated and methylated cpG sites, respectively. The red outlined lollipop corresponds to 
the 3' Ets site. Ovals indicate nucleosomes, with numbers below each indicating the nucleo-
some position relative to the MAGEA11 Tss. Right bent arrow indicates Tss. purple lines indicate 
histone h3 tails. Ac indicates acetylation.
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Life Technologies). The following primers were used: Outer 
PCR: 5'-GTGCTCACCT GGAGTCCAAA-3', Inner PCR: 
5'-TTCTTCCTCT TGATGCTGGC-3'. Primers were obtained 
from Integrated DNA Technologies.
DNA methylation analyses. One microgram gDNA was 
bisulfite converted using the EZ DNA Methylation Kit (Zymo 
Research). Bisulfite clonal sequencing of the MAGEA11 pro-
moter region was performed as described.10 Bisulfite pyrose-
quencing was performed to measure methylation of three CpG 
sites adjacent to the MAGEA11 TSS. Primers were (forward) 
5'-TTTTGTTGTA AATTTAGGGA AGTT-3', (reverse) 5'-bio-
tin-AACCCCACCC TTTATAAAAC TACC-3', and (sequenc-
ing) 5'-GGATGTGATT TTTATTGGTT-3'. Primers were 
obtained from Integrated DNA Technologies. PCR conditions 
were 10 min × 95 °C, followed by 48 cycles of (95 °C for 30 
sec, 57 °C for 30 sec, and 72 °C for one min). Pyrosequencing 
of the LINE-1 repetitive element was performed as described.19 
Pyrosequencing was performed using the PSQ HS96 system 
(Qiagen). Unmethylated and methylated genomic DNA were 
run as controls. Samples were analyzed in duplicate from sepa-
rate PCR reactions.
Drug treatments. Various prostate cell lines were treated with 
5-aza-2'-deoxycytidine (decitabine, DAC) and/or Trichostatin A 
(TSA). Decitabine and TSA (Sigma) were solubilized in phos-
phate buffered saline (PBS) and dimethyl sulfoxide (DMSO), 
respectively. For decitabine, cells were treated twice, on day 0 and 
day 2, and harvested on day 4. For TSA, cells were treated on day 
0 and harvested on day 1. For combination treatments, cells were 
treated with decitabine on days 0 and 2, with TSA on day 3, and 
harvested on day 4. Mithramycin A (MitA) (Sigma) was solubi-
lized in DMSO and added to LAPC-4 cells at 75, 125, or 200 
nM. Cell extracts were harvested one day post-treatment, and 
used for RT-qPCR or luciferase assays as described in Results. 
PC-3 cells were treated with PBS (vehicle) or decitabine on days 
0 and 3, and DMSO (vehicle) or MitA on days 2 and 4, and 
harvested for RT-qPCR analysis of MAGEA11 on day 5. As con-
trols for single drug treatments, PC-3 cells were harvested 5 d 
post-treatment with decitabine or four days post-treatment with 
MitA.
Chromatin immunoprecipitation (ChIP). ChIP was per-
formed as described.14 ChIP products were analyzed using end-
point PCR and agarose gel electrophoresis, or alternatively using 
qPCR. qPCR reactions were performed in triplicate using an 
Applied Biosystems 7300 System and qPCR MasterMix Plus 
for SYBR® with ROX master mix (AnaSpec). The region flank-
ing the MAGEA11 TSS was amplified using forward primer 
5'-CCTGCTGTAA ATCCAGGGAA-3', and reverse primer 
5'-CCCTCTGCCA CTCTCAAGAC-3'. Primers were from 
Integrated DNA Technologies. ChIP antibodies were H3K9ac 
(Upstate, Cat#06-599) and RNA Polymerase II (Abcam, Cat 
#ab5408).
Promoter luciferase assays. Four regions of the MAGEA11 
promoter (C1 through C4) were cloned into pGL3-Basic 
(Promega) using PCR. Methylation of promoter inserts and re-
ligation into pGL3-Basic were as described,18 except that KpnI 
and XhoI (Fermentas) were used for digestion. Methylation 
footprint could also indicate binding of a Sp1 family member. 
Resolution of these possibilities is of interest in future studies.
Materials and Methods
In silico gene expression analysis. Oncomine (Compendia 
Bioscience) was used for analysis of MAGEA11 expression in 
publically available human microarray data sets. Additional 
details and references are presented in the Results.
Human cell lines and clinical research tissues. Prostate 
cell lines and culture conditions were as described.10 HCT116 
wild type and DNMT1/3b single or double knockout (DKO) 
HCT116 cells and their culture conditions also were as 
described.21 Human benign prostatic hyperplasia (BP), andro-
gen-stimulated prostate cancer (AS), castration-recurrent pros-
tate cancer (CR), normal ovary (NO), and epithelial ovarian 
cancer (EOC) clinical samples were as described.10,18,19 All EOC 
tissues contained greater than 90% neoplastic cells. All human 
tissues were obtained under IRB-approved protocols at the 
University of North Carolina (prostate) or Roswell Park Cancer 
Institute (ovarian).
RNA and genomic DNA (gDNA) extractions. RNA was 
extracted using TRIzol (Invitrogen) according to the manufac-
turer’s instructions. Tissue homogenization was performed as 
described.18 RNAs were quantified using Nanodrop (Thermo 
Scientific) and RNA integrity was assessed using denaturing 
agarose gel electrophoresis. gDNAs were prepared using the 
Puregene kit (Qiagen).
Reverse transcriptase quantitative PCR (RT-qPCR). 
RT-qPCR was used to measure the expression of MAGEA1, 
NY-ESO-1, XAGE-1, and GAPDH as described.14,19 
For MAGEA11, the following primers were used: F: 
5'-GGAGACTCAG TTCCGCAGAG-3', R: 5'-TGGGACCACT 
GTAGTTGTGG-3'. Primers were obtained from Integrated 
DNA Technologies. Briefly, 1 μg of RNA was DNase-treated 
using the DNA-free kit (Ambion). cDNA was generated using 
the iScript cDNA synthesis kit (BioRad). Two microliters of 1:5 
cDNA sample dilutions were used for qPCR reactions. Standard 
curves were prepared using gel-purified end-point RT-PCR prod-
ucts amplified from testis RNA. All PCR reactions were per-
formed in triplicate using an Applied Biosystems 7300 System 
and qPCR MasterMix Plus for SYBR® with ROX master mix 
(AnaSpec).
Microarray analysis of MAGEA11 and CG gene expression. 
Affymetrix HG 1.0ST arrays were used to determine the expres-
sion of MAGEA11 and other CG genes in NO and EOC. Probe 
generation, array hybridization, and expression analyses were 
performed by the Next Generation Sequencing and Expression 
Analysis Core Facility at the University at Buffalo Center for 
Excellence in Bioinformatics. Samples included three NO and 
40 EOC. Correlation between MAGEA11 expression and other 
CG genes was determined using the Spearman’s test. Full expres-
sion data from the microarray analysis will be reported elsewhere.
Determination of the MAGEA11 transcriptional start site 
(TSS). RLM-RACE was used to map the MAGEA11 TSS in 
LAPC-4 cells, using the First Choice RLM-RACE kit (Ambion, 
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and methylated in vitro using 200 units of the 5'-GC-3' methyl-
ase CviP1 (New England Biolabs), or mock methylated without 
enzyme. gDNA was recovered using phenol-chloroform extrac-
tion and bisulfite converted using the EZ DNA methylation kit 
(Zymo). The resulting DNA served as template for PCR of the 
MAGEA11 promoter region, using unbiased primers to deter-
mine methylation status (forward primer 5'-TAAGAGGAGG 
ATTTTTTTGA GTGAG-3', reverse primer 5'-AAATAAAACC 
TCTCCATAAT TTCTCAA-3'), or using a combination of 
reverse primers selective for amplification of unmethylated (reverse 
primer 5'-CCTCTACCCA AATCACACCA TA-3') and methyl-
ated (reverse primer 5'-CCTCTACCCG AATCACACCA-3') 
DNA sequences. PCR products were recovered using gel purifi-
cation (Qiagen), cloned into pTOPO 4.1 (Invitrogen), and sub-
jected to Sanger sequencing. MethylViewer was used to analyze 
MAPit data.37
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reactions utilized M.SssI or HpaII methylases (New England 
Biolabs). The methylation status of promoter inserts was veri-
fied using HpaII or McrBc endonuclease (New England Biolabs) 
digestions. Transfections utilized Lipofectamine 2000 (Life 
Technologies). Cell extracts were harvested one day post-trans-
fection. The Dual-Luciferase Reporter Assay System (Promega) 
was used to determine promoter activity.
Sp1 siRNA knockdown. Pre-designed siRNAs targeting 
human Sp1 (s13319 [siSp1 #1] and s13320 [siSp1 #2]) were 
obtained from Ambion (Life Technologies), and siRNA Control 
Non-Targeting siRNA was obtained from Dharmacon. LAPC-4 
cells were transfected with siRNAs using the Lipofectamine 
2000 (Life Technologies) reverse transfection method. Cells 
were transfected with 25 nM siRNA at 0 and 24 h. Cell extracts 
were collected at 48 h and analyzed using western blot for Sp1, or 
RT-qPCR for MAGEA11.
Western blotting. Proteins were extracted using radioimmu-
noprecipitation assay (RIPA) buffer, and quantified using the 
Lowry assay (BioRad). Equal amounts of protein samples per lane 
were separated using NuPage SDS-PAGE gels (Life Technologies). 
Alternatively, cytosolic and nuclear protein extracts were pre-
pared using the NE-PER kit (Pierce). Sp1 was detected using 
Sp1 antibody (Santa Cruz, sc-14027) at 1:200 dilution. β-actin 
was detected using anti-actin antibody (Santa Cruz, sc-4778) at 
1:1000 dilution. Donkey anti-rabbit IgG-HRP secondary anti-
body (Santa Cruz, sc-2313) was used at 1:5000 dilution. Rabbit 
anti-mouse IgG-HRP (Santa Cruz, sc-358917) was used at 
1:5000 dilution. The Novex ECL HRP Chemiluminescence kit 
(Life Technologies) was used for protein detection.
Nucleosome occupancy at the MAGEA11 pro-
moter. Nucleosome occupancy was determined using the 
Methyltransferase Accessibility Protocol for individual templates 
(MAPit), also known as Nucleosome Occupancy and Methylome 
Sequencing (NOME-seq).33,36,60 Briefly, cell nuclei were isolated 
References
1. Akers SN, Odunsi K, Karpf AR. Regulation of cancer 
germline antigen gene expression: implications for 
cancer immunotherapy. Future Oncol 2010; 6:717-32; 
PMID:20465387
2. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, 
Old LJ. Cancer/testis antigens, gametogenesis and can-
cer. Nat Rev Cancer 2005; 5:615-25; PMID:16034368
3. Meek DW, Marcar L. MAGE-A antigens as targets 
in tumour therapy. Cancer Lett 2012; 324:126-32; 
PMID:22634429
4. Minges JT, Su S, Grossman G, Blackwelder AJ, 
Pop EA, Mohler JL, et al. Melanoma antigen-A11 
(MAGE-A11) enhances transcriptional activity by link-
ing androgen receptor dimers. J Biol Chem 2013; 
288:1939-52; PMID:23172223
5. Liu W, Cheng S, Asa SL, Ezzat S. The melanoma-
associated antigen A3 mediates fibronectin-controlled 
cancer progression and metastasis. Cancer Res 2008; 
68:8104-12; PMID:18829569
6. Cappell KM, Sinnott R, Taus P, Maxfield K, Scarbrough 
M, Whitehurst AW. Multiple cancer testis antigens 
function to support tumor cell mitotic fidelity. Mol 
Cell Biol 2012; 32:4131-40; PMID:22869527
7. Whitehurst AW, Xie Y, Purinton SC, Cappell KM, 
Swanik JT, Larson B, et al. Tumor antigen acrosin 
binding protein normalizes mitotic spindle function 
to promote cancer cell proliferation. Cancer Res 2010; 
70:7652-61; PMID:20876808
8. Whitehurst AW, Bodemann BO, Cardenas J, Ferguson 
D, Girard L, Peyton M, et al. Synthetic lethal screen 
identification of chemosensitizer loci in cancer cells. 
Nature 2007; 446:815-9; PMID:17429401
9. Renaud S, Loukinov D, Alberti L, Vostrov A, Kwon 
YW, Bosman FT, et al. BORIS/CTCFL-mediated tran-
scriptional regulation of the hTERT telomerase gene in 
testicular and ovarian tumor cells. Nucleic Acids Res 
2011; 39:862-73; PMID:20876690
10. Karpf AR, Bai S, James SR, Mohler JL, Wilson EM. 
Increased expression of androgen receptor coregulator 
MAGE-11 in prostate cancer by DNA hypomethyl-
ation and cyclic AMP. Mol Cancer Res 2009; 7:523-35; 
PMID:19372581
11. Ehrlich M. DNA hypomethylation in cancer cells. 
Epigenomics 2009; 1:239-59; PMID:20495664
12. Karpf AR. Epigenetic alterations in oncogen-
esis. Preface. Adv Exp Med Biol 2013; 754:v-vii; 
PMID:23189391
13. Cannuyer J, Loriot A, Parvizi GK, De Smet C. 
Epigenetic hierarchy within the MAGEA1 cancer-
germline gene: promoter DNA methylation dic-
tates local histone modifications. PLoS One 2013; 
8:e58743; PMID:23472218
14. James SR, Link PA, Karpf AR. Epigenetic regula-
tion of X-linked cancer/germline antigen genes by 
DNMT1 and DNMT3b. Oncogene 2006; 25:6975-
85; PMID:16715135
15. Link PA, Gangisetty O, James SR, Woloszynska-Read 
A, Tachibana M, Shinkai Y, et al. Distinct roles for 
histone methyltransferases G9a and GLP in cancer 
germ-line antigen gene regulation in human cancer 
cells and murine embryonic stem cells. Mol Cancer Res 
2009; 7:851-62; PMID:19531572
16. Wischnewski F, Pantel K, Schwarzenbach H. Promoter 
demethylation and histone acetylation mediate gene 
expression of MAGE-A1, -A2, -A3, and -A12 in 
human cancer cells. Mol Cancer Res 2006; 4:339-49; 
PMID:16687489
17. Karpf AR, Lasek AW, Ririe TO, Hanks AN, Grossman 
D, Jones DA. Limited gene activation in tumor and 
normal epithelial cells treated with the DNA meth-
yltransferase inhibitor 5-aza-2'-deoxycytidine. Mol 
Pharmacol 2004; 65:18-27; PMID:14722233
18. Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi 
K, Karpf AR. DNA methylation-dependent regula-
tion of BORIS/CTCFL expression in ovarian cancer. 
Cancer Immun 2007; 7:21; PMID:18095639
19. Woloszynska-Read A, Mhawech-Fauceglia P, Yu J, 
Odunsi K, Karpf AR. Intertumor and intratumor 
NY-ESO-1 expression heterogeneity is associated with 
promoter-specific and global DNA methylation status 
in ovarian cancer. Clin Cancer Res 2008; 14:3283-90; 
PMID:18519754
www.landesbioscience.com Epigenetics 863
54. Mancini DN, Singh SM, Archer TK, Rodenhiser DI. 
Site-specific DNA methylation in the neurofibro-
matosis (NF1) promoter interferes with binding of 
CREB and SP1 transcription factors. Oncogene 1999; 
18:4108-19; PMID:10435592
55. Mulero-Navarro S, Carvajal-Gonzalez JM, Herranz 
M, Ballestar E, Fraga MF, Ropero S, et al. The dioxin 
receptor is silenced by promoter hypermethylation in 
human acute lymphoblastic leukemia through inhibi-
tion of Sp1 binding. Carcinogenesis 2006; 27:1099-
104; PMID:16410262
56. Butler JE, Kadonaga JT. The RNA polymerase II 
core promoter: a key component in the regulation 
of gene expression. Genes Dev 2002; 16:2583-92; 
PMID:12381658
57. Darst RP, Pardo CE, Pondugula S, Gangaraju VK, 
Nabilsi NH, Bartholomew B, et al. Simultaneous single-
molecule detection of endogenous C-5 DNA methyla-
tion and chromatin accessibility using MAPit. Methods 
Mol Biol 2012; 833:125-41; PMID:22183592
58. Lin JC, Jeong S, Liang G, Takai D, Fatemi M, Tsai YC, 
et al. Role of nucleosomal occupancy in the epigenetic 
silencing of the MLH1 CpG island. Cancer Cell 2007; 
12:432-44; PMID:17996647
59. Delmas AL, Riggs BM, Pardo CE, Dyer LM, Darst 
RP, Izumchenko EG, et al. WIF1 is a frequent target 
for epigenetic silencing in squamous cell carcino-
ma of the cervix. Carcinogenesis 2011; 32:1625-33; 
PMID:21873353
60. Kilgore JA, Hoose SA, Gustafson TL, Porter W, 
Kladde MP. Single-molecule and population probing 
of chromatin structure using DNA methyltransferases. 
Methods 2007; 41:320-32; PMID:17309843
61. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-
Weiler M, Liang W, et al. Gene expression profiles of 
prostate cancer reveal involvement of multiple molecu-
lar pathways in the metastatic process. BMC Cancer 
2007; 7:64; PMID:17430594
62. Nanni S, Priolo C, Grasselli A, D’Eletto M, Merola 
R, Moretti F, et al. Epithelial-restricted gene profile 
of primary cultures from human prostate tumors: 
a molecular approach to predict clinical behavior 
of prostate cancer. Mol Cancer Res 2006; 4:79-92; 
PMID:16513839
63. Cancer Genome Atlas Research Network. Integrated 
genomic analyses of ovarian carcinoma. Nature 2011; 
474:609-15; PMID:21720365
64. Hu N, Clifford RJ, Yang HH, Wang C, Goldstein AM, 
Ding T, et al. Genome wide analysis of DNA copy 
number neutral loss of heterozygosity (CNNLOH) 
and its relation to gene expression in esophageal squa-
mous cell carcinoma. BMC Genomics 2010; 11:576; 
PMID:20955586
65. Aoyagi K, Minashi K, Igaki H, Tachimori Y, Nishimura 
T, Hokamura N, et al. Artificially induced epithelial-
mesenchymal transition in surgical subjects: its impli-
cations in clinical and basic cancer research. PLoS One 
2011; 6:e18196; PMID:21533028
66. Cutcliffe C, Kersey D, Huang CC, Zeng Y, Walterhouse 
D, Perlman EJ; Renal Tumor Committee of the 
Children’s Oncology Group. Clear cell sarcoma of the 
kidney: up-regulation of neural markers with activation 
of the sonic hedgehog and Akt pathways. Clin Cancer 
Res 2005; 11:7986-94; PMID:16299227
67. Zhao H, Ljungberg B, Grankvist K, Rasmuson T, 
Tibshirani R, Brooks JD. Gene expression profiling 
predicts survival in conventional renal cell carcinoma. 
PLoS Med 2006; 3:e13; PMID:16318415
37. Pardo CE, Carr IM, Hoffman CJ, Darst RP, Markham 
AF, Bonthron DT, et al. MethylViewer: computa-
tional analysis and editing for bisulfite sequencing and 
methyltransferase accessibility protocol for individual 
templates (MAPit) projects. Nucleic Acids Res 2011; 
39:e5; PMID:20959287
38. Bai L, Morozov AV. Gene regulation by nucleo-
some positioning. Trends Genet 2010; 26:476-83; 
PMID:20832136
39. Bai S, He B, Wilson EM. Melanoma antigen gene pro-
tein MAGE-11 regulates androgen receptor function by 
modulating the interdomain interaction. Mol Cell Biol 
2005; 25:1238-57; PMID:15684378
40. Jurk M, Kremmer E, Schwarz U, Förster R, Winnacker 
EL. MAGE-11 protein is highly conserved in higher 
organisms and located predominantly in the nucleus. 
Int J Cancer 1998; 75:762-6; PMID:9495246
41. Su S, Blackwelder AJ, Grossman G, Minges JT, 
Yuan L, Young SL, et al. Primate-specific melanoma 
antigen-A11 regulates isoform-specific human proges-
terone receptor-B transactivation. J Biol Chem 2012; 
287:34809-24; PMID:22891251
42. Askew EB, Bai S, Blackwelder AJ, Wilson EM. 
Transcriptional synergy between melanoma antigen 
gene protein-A11 (MAGE-11) and p300 in androgen 
receptor signaling. J Biol Chem 2010; 285:21824-36; 
PMID:20448036
43. Su S, Minges JT, Grossman G, Blackwelder AJ, Mohler 
JL, Wilson EM. Proto-oncogene activity of Melanoma 
antigen-A11 (MAGE-A11) regulates Retinoblastoma-
related p107 and E2F1. J Biol Chem 2013; In press.
44. Berman BP, Weisenberger DJ, Aman JF, Hinoue 
T, Ramjan Z, Liu Y, et al. Regions of focal DNA 
hypermethylation and long-range hypomethylation 
in colorectal cancer coincide with nuclear lamina-
associated domains. Nat Genet 2012; 44:40-6; 
PMID:22120008
45. Reddy KL, Feinberg AP. Higher order chromatin orga-
nization in cancer. Semin Cancer Biol 2013; 23:109-
15; PMID:23266653
46. Karpf AR. A potential role for epigenetic modula-
tory drugs in the enhancement of cancer/germ-line 
antigen vaccine efficacy. Epigenetics 2006; 1:116-20; 
PMID:17786175
47. Pandiyan K, You JS, Yang X, Dai C, Zhou XJ, Baylin 
SB, et al. Functional DNA demethylation is accom-
panied by chromatin accessibility. Nucleic Acids Res 
2013; 41:3973-85; PMID:23408854
48. Portela A, Liz J, Nogales V, Setién F, Villanueva A, 
Esteller M. DNA methylation determines nucleosome 
occupancy in the 5'-CpG islands of tumor suppressor 
genes. Oncogene 2013; PMID:23686312
49. Bi FF, Li D, Yang Q. Hypomethylation of ETS 
Transcription Factor Binding Sites and Upregulation of 
PARP1 Expression in Endometrial Cancer. Biomed Res 
Int 2013; 2013:946268; PMID:23762867
50. Hollenhorst PC, McIntosh LP, Graves BJ. Genomic 
and biochemical insights into the specificity of ETS 
transcription factors. Annu Rev Biochem 2011; 
80:437-71; PMID:21548782
51. Harrington MA, Jones PA, Imagawa M, Karin M. 
Cytosine methylation does not affect binding of tran-
scription factor Sp1. Proc Natl Acad Sci U S A 1988; 
85:2066-70; PMID:3281160
52. Höller M, Westin G, Jiricny J, Schaffner W. Sp1 tran-
scription factor binds DNA and activates transcription 
even when the binding site is CpG methylated. Genes 
Dev 1988; 2:1127-35; PMID:3056778
53. Clark SJ, Harrison J, Molloy PL. Sp1 binding is 
inhibited by (m)Cp(m)CpG methylation. Gene 1997; 
195:67-71; PMID:9300822
20. Woloszynska-Read A, Zhang W, Yu J, Link PA, 
Mhawech-Fauceglia P, Collamat G, et al. Coordinated 
cancer germline antigen promoter and global DNA 
hypomethylation in ovarian cancer: association with 
the BORIS/CTCF expression ratio and advanced stage. 
Clin Cancer Res 2011; 17:2170-80; PMID:21296871
21. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, 
Schuebel KE, et al. DNMT1 and DNMT3b cooperate 
to silence genes in human cancer cells. Nature 2002; 
416:552-6; PMID:11932749
22. Song L, James SR, Kazim L, Karpf AR. Specific method 
for the determination of genomic DNA methylation by 
liquid chromatography-electrospray ionization tandem 
mass spectrometry. Anal Chem 2005; 77:504-10; 
PMID:15649046
23. Rao M, Chinnasamy N, Hong JA, Zhang Y, Zhang 
M, Xi S, et al. Inhibition of histone lysine methylation 
enhances cancer-testis antigen expression in lung cancer 
cells: implications for adoptive immunotherapy of can-
cer. Cancer Res 2011; 71:4192-204; PMID:21546573
24. Yoshida M, Kijima M, Akita M, Beppu T. Potent and 
specific inhibition of mammalian histone deacetylase 
both in vivo and in vitro by trichostatin A. J Biol Chem 
1990; 265:17174-9; PMID:2211619
25. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics 
in human disease and prospects for epigenetic therapy. 
Nature 2004; 429:457-63; PMID:15164071
26. Campbell MJ, Turner BM. Altered histone modifica-
tions in cancer. Adv Exp Med Biol 2013; 754:81-107; 
PMID:22956497
27. De Plaen E, Naerhuyzen B, De Smet C, Szikora JP, 
Boon T. Alternative promoters of gene MAGE4a. 
Genomics 1997; 40:305-13; PMID:9119398
28. De Smet C, De Backer O, Faraoni I, Lurquin C, 
Brasseur F, Boon T. The activation of human gene 
MAGE-1 in tumor cells is correlated with genome-
wide demethylation. Proc Natl Acad Sci U S A 1996; 
93:7149-53; PMID:8692960
29. Li L, Davie JR. The role of Sp1 and Sp3 in normal 
and cancer cell biology. Ann Anat 2010; 192:275-83; 
PMID:20810260
30. Blume SW, Snyder RC, Ray R, Thomas S, Koller 
CA, Miller DM. Mithramycin inhibits SP1 binding 
and selectively inhibits transcriptional activity of the 
dihydrofolate reductase gene in vitro and in vivo. J Clin 
Invest 1991; 88:1613-21; PMID:1834700
31. Henikoff S. Nucleosomes at active promoters: 
unforgettable loss. Cancer Cell 2007; 12:407-9; 
PMID:17996642
32. Pondugula S, Kladde MP. Single-molecule analysis 
of chromatin: changing the view of genomes one 
molecule at a time. J Cell Biochem 2008; 105:330-7; 
PMID:18615586
33. Miranda TB, Kelly TK, Bouazoune K, Jones PA. 
Methylation-sensitive single-molecule analysis of chro-
matin structure. Current protocols in molecular biol-
ogy/edited by Frederick M Ausubel [et al.] 2010; 
Chapter 21:Unit 21 17 1-6.
34. You JS, Kelly TK, De Carvalho DD, Taberlay PC, 
Liang G, Jones PA. OCT4 establishes and maintains 
nucleosome-depleted regions that provide additional 
layers of epigenetic regulation of its target genes. 
Proc Natl Acad Sci U S A 2011; 108:14497-502; 
PMID:21844352
35. Jessen WJ, Dhasarathy A, Hoose SA, Carvin CD, 
Risinger AL, Kladde MP. Mapping chromatin structure 
in vivo using DNA methyltransferases. Methods 2004; 
33:68-80; PMID:15039089
36. Pardo CE, Darst RP, Nabilsi NH, Delmas AL, Kladde 
MP. Simultaneous single-molecule mapping of protein-
DNA interactions and DNA methylation by MAPit. 
Current protocols in molecular biology/edited by 
Frederick M Ausubel [et al.] 2011; Chapter 21:Unit 21 
2.
